Infinity Pharma Issues Phase 1 Data from Clinical Trial of IPI-145, Shows Tolerance
June 24, 2013 at 07:49 AM EDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active across a broad range
